2022年癫痫领域十大研究进展

doi:10.3969/j.issn.1672-6731.2023.03.001

中国现代神经疾病杂志 ›› 2023, Vol. 23 ›› Issue (3): 149-155. doi: 10.3969/j.issn.1672-6731.2023.03.001

2 2022年癫痫领域十大研究进展

王群^1,2, 单伟^1,2, 杨华俊³

1 100070 首都医科大学附属北京天坛医院神经病学中心癫痫科国家神经系统疾病临床医学研究中心;
2 100069 北京脑重大疾病研究院;
3 100093 科大学三博脑科医院神经内科

收稿日期:2023-02-28 出版日期:2023-03-25 发布日期:2023-04-10
通讯作者: 王群,Email:wangq@ccmu.edu.cn
基金资助:
国家重点研发计划“常见多发病防治研究”重点专项（项目编号：2022YFC2503800）；国家自然科学基金青年科学基金资助项目（项目编号：82201504）；北京市科技新星基金资助项目（项目编号：Z211100002121047）；北京市科技新星交叉课题（项目编号：20220484159）

Research progress on epilepsy in 2022

WANG Qun^1,2, SHAN Wei^1,2, YANG Hua-jun³

1 Department of Epilepsy, Center of Neurology, Beijing Tiantan Hospital, Capital Medical University;China National Clinical Research Center for Neurological Diseases, Beijing 100070, China;
2 Beijing Institute for Brain Disorders, Beijing 100069, China;
3 Department of Neurology, Sanbo Brain Hospital, Capital Medical University, Beijing 100093, China

Received:2023-02-28 Online:2023-03-25 Published:2023-04-10
Supported by:
This study was supported by National Key Research and Development Program of China "Common Disease Prevention and Control Research" Key Project (No. 2022YFC2503800), the National Natural Science Foundation of China for Young Scientists (No. 82201504), Beijing Science and Technology New Star Project (No. Z211100002121047), and Beijing Science and Technology New Star Cross Project (No. 20220484159).

摘要/Abstract

摘要： 2022 年有关癫痫的基础与临床研究取得了引人瞩目且具有重要意义的成果，主要集中于癫痫的诊断与评估、神经重症患者脑电活动的干预、抗癫痫发作药物和疾病修饰治疗药物的应用、神经调控、基因治疗等领域。本文拟结合我国当前癫痫科研与临床需求，梳理2022 年各相关领域的最新研究进展，并以此展望癫痫诊断与治疗发展的新方向。

关键词: 癫痫, 抗惊厥药, 综述

Abstract: In 2022, scholars in the field of epilepsy at home and abroad have contributed many significant research achievements in both the basic and clinical aspects of epilepsy, mainly focusing on the diagnosis and evaluation of epilepsy, the intervention of electroence (EEG) activity in severe neurological disease, the application of antiepileptic seizure medicine (ASM) and disease modifying therapy (DMT) drugs, neuromodulation, gene therapy, etc. This article combined the current needs of epilepsy research in China with the author's own understanding, summarized the new progress in the field of epilepsy mentioned above in 2022, and looks forward to the new development direction of epilepsy research.

Key words: Epilepsy, Anticonvulsants, Review

王群, 单伟, 杨华俊. 2022年癫痫领域十大研究进展[J]. 中国现代神经疾病杂志, 2023, 23(3): 149-155.

WANG Qun, SHAN Wei, YANG Hua-jun. Research progress on epilepsy in 2022[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2023, 23(3): 149-155.

http://journal11.magtechjournal.com/cjcnn/CN/Y2023/V23/I3/149

参考文献

[1] Laghouati E, Studer F, Depaulis A, Guillemain I. Early alterations of the neuronal network processing whisker-related sensory signal during absence epileptogenesis[J]. Epilepsia, 2022, 63:497-509.
[2] Park DK, Kim W, Thornburg OS, McBrian DK, McKhann GM, Feldstein NA, Maddocks AB, Gonzalez E, Shen MY, Akman C, Provenzano FA. Convolutional neural network-aided tuber segmentation in tuberous sclerosis complex patients correlates with electroencephalogram[J]. Epilepsia, 2022, 63:1530-1541.
[3] Neal A, Bouet R, Lagarde S, Ostrowsky-Coste K, Maillard L, Kahane P, Touraine R, Catenoix H, Montavont A, Isnard J, Arzimanoglou A, Hermier M, Guenot M, Bartolomei F, Rheims S, Jung J. Epileptic spasms are associated with increased stereo-electroencephalography derived functional connectivity in tuberous sclerosis complex[J]. Epilepsia, 2022, 63:2359-2370.
[4] Boulogne S, Pizzo F, Chatard B, Roehri N, Catenoix H, Ostrowsky-Coste K, Giusiano B, Guenot M, Carron R, Bartolomei F, Rheims S. Functional connectivity and epileptogenicity of nodular heterotopias:a single-pulse stimulation study[J]. Epilepsia, 2022, 63:961-973.
[5] Fleury M, Buck S, Binding LP, Caciagli L, Vos SB, Winston GP, Thompson PJ, Koepp MJ, Duncan JS, Sidhu MK. Episodic memory network connectivity in temporal lobe epilepsy[J]. Epilepsia, 2022, 63:2597-2622.
[6] Li R, Deng C, Wang X, Zou T, Biswal B, Guo D, Xiao B, Zhang X, Cheng JL, Liu D, Yang M, Chen H, Wu Q, Feng L. Interictal dynamic network transitions in mesial temporal lobe epilepsy[J]. Epilepsia, 2022, 63:2242-2255.
[7] Wirrell EC, Nabbout R, Scheffer IE, Alsaadi T, Bogacz A, French JA, Hirsch E, Jain S, Kaneko S, Riney K, Samia P, Snead OC, Somerville E, Specchio N, Trinka E, Zuberi SM, Balestrini S, Wiebe S, Cross JH, Perucca E, Moshé SL, Tinuper P. Methodology for classification and definition of epilepsy syndromes with list of syndromes:report of the ILAE Task Force on Nosology and Definitions[J]. Epilepsia, 2022, 63:1333-1348.
[8] Zuberi SM, Wirrell E, Yozawitz E, Wilmshurst JM, Specchio N, Riney K, Pressler R, Auvin S, Samia P, Hirsch E, Galicchio S, Triki C, Snead OC, Wiebe S, Cross JH, Tinuper P, Scheffer IE, Perucca E, Moshé SL, Nabbout R. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants:position statement by the ILAE Task Force on Nosology and Definitions[J]. Epilepsia, 2022, 63:1349-1397.
[9] Specchio N, Wirrell EC, Scheffer IE, Nabbout R, Riney K, Samia P, Guerreiro M, Gwer S, Zuberi SM, Wilmshurst JM, Yozawitz E, Pressler R, Hirsch E, Wiebe S, Cross HJ, Perucca E, Moshé SL, Tinuper P, Auvin S. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood:position paper by the ILAE Task Force on Nosology and Definitions[J]. Epilepsia, 2022, 63:1398-1442.
[10] Riney K, Bogacz A, Somerville E, Hirsch E, Nabbout R, Scheffer IE, Zuberi SM, Alsaadi T, Jain S, French J, Specchio N, Trinka E, Wiebe S, Auvin S, Cabral-Lim L, Naidoo A, Perucca E, Moshé SL, Wirrell EC, Tinuper P. International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age:position statement by the ILAE Task Force on Nosology and Definitions[J]. Epilepsia, 2022, 63:1443-1474.
[11] Hirsch E, French J, Scheffer IE, Bogacz A, Alsaadi T, Sperling MR, Abdulla F, Zuberi SM, Trinka E, Specchio N, Somerville E, Samia P, Riney K, Nabbout R, Jain S, Wilmshurst JM, Auvin S, Wiebe S, Perucca E, Moshé SL, Tinuper P, Wirrell EC. ILAE definition of the idiopathic generalized epilepsy syndromes:position statement by the ILAE Task Force on Nosology and Definitions[J]. Epilepsia, 2022, 63:1475-1499.
[12] Leal-Pardinas F, Truty R, McKnight DA, Johnson B, Morales A, Bristow SL, Yar Pang T, Cohen-Pfeffer J, Izzo E, Sankar R, Koh S, Wirrell EC, Millichap JJ, Aradhya S. Value of genetic testing for pediatric epilepsy:driving earlier diagnosis of ceroid lipofuscinosis type 2 Batten disease[J]. Epilepsia, 2022, 63:e68-73.
[13] Hammer MF, Pan Y, Cumbay M, Pendziwiat M, Afawi Z, Goldberg-Stern H, Johnstone L, Helbig I, Cummins TR. Whole exome sequencing and co-expression analysis identify an SCN1A variant that modifies pathogenicity in a family with genetic epilepsy and febrile seizures plus[J]. Epilepsia, 2022, 63:1970-1980.
[14] Ahn SJ, Oh J, Kim DY, Son H, Hwang S, Shin HR, Kim EY, Lee HS, Lee WJ, Moon J, Lee ST, Jung KH, Park KI, Jung KY, Lee S, Yu KS, Chu K, Lee SK. Effects of CYP2C19 genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsy[J]. Epilepsia, 2022, 63:2958-2969.
[15] Coombs ID, Ziobro J, Krotov V, Surtees TL, Cull-Candy SG, Farrant M. A gain-of-function GRIA2 variant associated with neurodevelopmental delay and seizures:functional characterization and targeted treatment[J]. Epilepsia, 2022, 63:e156-163.
[16] Maillard PY, Baer S, Schaefer É, Desnous B, Villeneuve N, Lépine A, Fabre A, Lacoste C, El Chehadeh S, Piton A, Porter LF, Perriard C, Wardé MA, Spitz MA, Laugel V, Lesca G, Putoux A, Ville D, Mignot C, Héron D, Nabbout R, Barcia G, Rio M, Roubertie A, Meyer P, Paquis-Flucklinger V, Patat O, Lefranc J, Gerard M, de Bellescize J, Villard L, De Saint Martin A, Milh M; Epigen Consortium. Molecular and clinical descriptions of patients with GABAA receptor gene variants (GABRA1, GABRB2, GABRB3, GABRG2):a cohort study, review of literature, and genotype-phenotype correlation[J]. Epilepsia, 2022, 63:2519-2533.
[17] Striano P, Auvin S, Collins A, Horvath R, Scheffer IE, Tzadok M, Miller I, Kay Koenig M, Lacy A, Davis R, Garcia-Cazorla A, Saneto RP, Brandabur M, Blair S, Koutsoukos T, De Vivo D. A randomized, double-blind trial of triheptanoin for drug-resistant epilepsy in glucose transporter 1 deficiency syndrome[J]. Epilepsia, 2022, 63:1748-1760.
[18] Mullan KA, Anderson A, Shi YW, Ding JH, Ng CC, Chen Z, Baum L, Cherny S, Petrovski S, Sham PC, Lim KS, Liao WP, Kwan P. Potential role of regulatory DNA variants in modifying the risk of severe cutaneous reactions induced by aromatic anti-seizure medications[J]. Epilepsia, 2022, 63:936-949.
[19] Halliday A, Duncan A, Cheung M, Boston RC, Apiwattanakul M, Camacho X, Bowden S, D'Souza W. Second-line immunotherapy and functional outcomes in autoimmune encephalitis:a systematic review and individual patient data meta-analysis[J]. Epilepsia, 2022, 63:2214-2224.
[20] Makridis KL, Friedo AL, Kellinghaus C, Losch FP, Schmitz B, Boßelmann C, Kaindl AM. Successful treatment of adult Dravet syndrome patients with cenobamate[J]. Epilepsia, 2022, 63:e164-171.
[21] Gataullina S, Galvani G, Touchet S, Nous C, Lemaire É, Laschet J, Chiron C, Dulac O, Dossi E, Brion JD, Messaoudi S, Alami M, Huberfeld G. GluN2C selective inhibition is a target to develop new antiepileptic compounds[J]. Epilepsia, 2022, 63:2911-2924.
[22] Hahn CD, Jiang Y, Villanueva V, Zolnowska M, Arkilo D, Hsiao S, Asgharnejad M, Dlugos D. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTR)[J]. Epilepsia, 2022, 63:2671-2683.
[23] Hurley EN, Ellaway CJ, Johnson AM, Truong L, Gordon R, Galettis P, Martin JH, Lawson JA. Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome:a phase 1 clinical trial[J]. Epilepsia, 2022, 63:1736-1747.
[24] Riban V, Heulard I, Reversat L, Si Hocine H, Verleye M. Stiripentol inhibits spike-and -wave discharges in animal models of absence seizures:a new mechanism of action involving T-type calcium channels[J]. Epilepsia, 2022, 63:1200-1210.
[25] Wu JY, Cock HR, Devinsky O, Joshi C, Miller I, Roberts CM, Sanchez-Carpintero R, Checketts D, Sahebkar F. Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex:post hoc analysis of randomized controlled phase 3 trial GWPCARE6[J]. Epilepsia, 2022, 63:1189-1199.
[26] Schoonjans AS, Roosens L, Dewals W, Paelinck BP, Ceulemans B. Therapeutic drug monitoring of fenfluramine in clinical practice:pharmacokinetic variability and impact of concomitant antiseizure medications[J]. Epilepsia, 2022, 63:686-696.
[27] Kahlig KM, Scott L, Hatch RJ, Griffin A, Martinez Botella G, Hughes ZA, Wittmann M. The novel persistent sodium current inhibitor PRAX-562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers[J]. Epilepsia, 2022, 63:697-708.
[28] Najm I, Lal D, Alonso Vanegas M, Cendes F, Lopes-Cendes I, Palmini A, Paglioli E, Sarnat HB, Walsh CA, Wiebe S, Aronica E, Baulac S, Coras R, Kobow K, Cross JH, Garbelli R, Holthausen H, Rössler K, Thom M, El-Osta A, Lee JH, Miyata H, Guerrini R, Piao YS, Zhou D, Blümcke I. The ILAE consensus classification of focal cortical dysplasia:an update proposed by an ad hoc task force of the ILAE diagnostic methods commission[J]. Epilepsia, 2022, 63:1899-1919.
[29] Jehi L, Jette N, Kwon CS, Josephson CB, Burneo JG, Cendes F, Sperling MR, Baxendale S, Busch RM, Triki CC, Cross JH, Ekstein D, Englot DJ, Luan G, Palmini A, Rios L, Wang X, Roessler K, Rydenhag B, Ramantani G, Schuele S, Wilmshurst JM, Wilson S, Wiebe S. Timing of referral to evaluate for epilepsy surgery:Expert Consensus Recommendations from the Surgical Therapies Commission of the International League Against Epilepsy[J]. Epilepsia, 2022, 63:2491-2506.
[30] Varatharajah Y, Joseph B, Brinkmann B, Morita-Sherman M, Fitzgerald Z, Vegh D, Nair D, Burgess R, Cendes F, Jehi L, Worrell G. Quantitative analysis of visually reviewed normal scalp EEG predicts seizure freedom following anterior temporal lobectomy[J]. Epilepsia, 2022, 63:1630-1642.
[31] Sinclair B, Cahill V, Seah J, Kitchen A, Vivash LE, Chen Z, Malpas CB, O'Shea MF, Desmond PM, Hicks RJ, Morokoff AP, King JA, Fabinyi GC, Kaye AH, Kwan P, Berkovic SF, Law M, O'Brien TJ. Machine learning approaches for imaging-based prognostication of the outcome of surgery for mesial temporal lobe epilepsy[J]. Epilepsia, 2022, 63:1081-1092.
[32] Klodowski DA, George BJ, Sperling MR. Seizure latency and epilepsy localization as predictors of recurrence following epilepsy surgery[J]. Epilepsia, 2022, 63:1074-1080.
[33] Yossofzai O, Fallah A, Maniquis C, Wang S, Ragheb J, Weil AG, Brunette-Clement T, Andrade A, Ibrahim GM, Mitsakakis N, Widjaja E. Development and validation of machine learning models for prediction of seizure outcome after pediatric epilepsy surgery[J]. Epilepsia, 2022, 63:1956-1969.
[34] Castro-Villablanca F, Moeller F, Pujar S, D'Arco F, Scott RC, Tahir MZ, Tisdall M, Cross JH, Eltze C. Seizure outcome determinants in children after surgery for single unilateral lesions on magnetic resonance imaging:role of preoperative ictal and interictal electroencephalography[J]. Epilepsia, 2022, 63:3168-3179.
[35] Johnson KJ, Moy B, Rensing N, Robinson A, Ly M, Chengalvala R, Wong M, Galindo R. Functional neuropathology of neonatal hypoxia-ischemia by single-mouse longitudinal electroencephalography[J]. Epilepsia, 2022, 63:3037-3050.
[36] Lin JR, Cheng JF, Liu YT, Hsu TR, Lin KM, Chen C, Lin CL, Tsai MH, Tsai JW. Novel lissencephaly-associated DCX variants in the C-terminal DCX domain affect microtubule binding and dynamics[J]. Epilepsia, 2022, 63:1253-1265.
[37] Nagib MM, Zhang S, Yasmen N, Li L, Hou R, Yu Y, Boda VK, Wu Z, Li W, Jiang J. Inhibition of TRPC3 channels by a novel pyrazole compound confers antiseizure effects[J]. Epilepsia, 2022, 63:1003-1015.
[38] Kovermann P, Kolobkova Y, Franzen A, Fahlke C. Mutations associated with epileptic encephalopathy modify EAAT2 anion channel function[J]. Epilepsia, 2022, 63:388-401.
[39] Astner-Rohracher A, Zimmermann G, Avigdor T, Abdallah C, Barot N, Brázdil M, Doležalová I, Gotman J, Hall JA, Ikeda K, Kahane P, Kalss G, Kokkinos V, Leitinger M, Mindruta I, Minotti L, Mizera MM, Oane I, Richardson M, Schuele SU, Trinka E, Urban A, Whatley B, Dubeau F, Frauscher B. Development and validation of the 5-SENSE score to predict focality of the seizure-onset zone as assessed by stereoelectroencephalography[J]. JAMA Neurol, 2022, 79:70-79.
[40] Chen Z, Maturana MI, Burkitt AN, Cook MJ, Grayden DB. High-frequency oscillations in epilepsy:what have we learned and what needs to be addressed[J]. Neurology, 2021, 96:439-448.
[41] Pennell PB, Karanam A, Meador KJ, Gerard E, Kalayjian L, Penovich P, Matthews A, McElrath TM, Birnbaum AK; MONEAD Study Group. Antiseizure medication concentrations during pregnancy:results from the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study[J]. JAMA Neurol, 2022, 79:370-379.
[42] Li Y, Meador KJ. Epilepsy and pregnancy[J]. Continuum (Minneap Minn), 2022, 28:34-54.
[43] Henson T, Rawanduzy C, Salazar M, Sebastian A, Weber H, Al-Mufti F, Mayer SA. Outcome and prognostication after cardiac arrest[J]. Ann NY Acad Sci, 2022, 1508:23-34.
[44] Ruijter BJ, Keijzer HM, Tjepkema-Cloostermans MC, Blans MJ, Beishuizen A, Tromp SC, Scholten E, Horn J, van Rootselaar AF, Admiraal MM, van den Bergh WM, Elting JJ, Foudraine NA, Kornips FHM, van Kranen-Mastenbroek VHJM, Rouhl RPW, Thomeer EC, Moudrous W, Nijhuis FAP, Booij SJ, Hoedemaekers CWE, Doorduin J, Taccone FS, van der Palen J, van Putten MJAM, Hofmeijer J; TELSTAR Investigators. Treating rhythmic and periodic EEG patterns in comatose survivors of cardiac arrest[J]. N Engl J Med, 2022, 386:724-734.
[45] Phan J, Ramos M, Soares T, Parmar MS. Poststroke seizure and epilepsy:a review of incidence, risk factors, diagnosis, pathophysiology, and pharmacological therapies[J]. Oxid Med Cell Longev, 2022:ID7692215.
[46] Peter-Derex L, Philippeau F, Garnier P, André-Obadia N, Boulogne S, Catenoix H, Convers P, Mazzola L, Gouttard M, Esteban M, Fontaine J, Mechtouff L, Ong E, Cho TH, Nighoghossian N, Perreton N, Termoz A, Haesebaert J, Schott AM, Rabilloud M, Pivot C, Dhelens C, Filip A, Berthezène Y, Rheims S, Boutitie F, Derex L. Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH):a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Neurol, 2022, 21:781-791.
[47] Chamberlain JM, Kapur J, Shinnar S, Elm J, Holsti M, Babcock L, Rogers A, Barsan W, Cloyd J, Lowenstein D, Bleck TP, Conwit R, Meinzer C, Cock H, Fountain NB, Underwood E, Connor JT, Silbergleit R; Neurological Emergencies Treatment Trials; Pediatric Emergency Care Applied Research Network Investigators. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT):a double-blind, responsive-adaptive, randomised controlled trial[J]. Lancet, 2020, 395:1217-1224.
[48] Nakamura K, Marushima A, Takahashi Y, Mochizuki M, Kimura A, Fukuda Y, Asami M, Nakamoto H, Egawa S, Kaneko J, Unemoto K, Kondo Y, Yonekawa C, Uchida M, Hoshiyama E, Yamada T, Maruo K, Ishikawa E, Matsumaru Y, Inoue Y; IENE ECT with the LIFE Study Group. Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for adult convulsive status epilepticus:a multicentre non-inferiority randomised control trial[J]. J Neurol Neurosurg Psychiatry, 2023, 94:42-48.
[49] Tabaee Damavandi P, Fabin N, Giossi R, Matricardi S, Del Giovane C, Striano P, Meletti S, Brigo F, Trinka E, Lattanzi S. Efficacy and safety of fenfluramine in epilepsy:a systematic review and meta-analysis[J]. Neurol Ther, 2023, 12:669-686.
[50] Knupp KG, Scheffer IE, Ceulemans B, Sullivan JE, Nickels KC, Lagae L, Guerrini R, Zuberi SM, Nabbout R, Riney K, Shore S, Agarwal A, Lock M, Farfel GM, Galer BS, Gammaitoni AR, Davis R, Gil-Nagel A. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome:a randomized clinical trial[J]. JAMA Neurol, 2022, 79:554-564.
[51] Knight EMP, Amin S, Bahi-Buisson N, Benke TA, Cross JH, Demarest ST, Olson HE, Specchio N, Fleming TR, Aimetti AA, Gasior M, Devinsky O; Marigold Trial Group. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder:results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial[J]. Lancet Neurol, 2022, 21:417-427.
[52] Dalic LJ, Warren AEL, Bulluss KJ, Thevathasan W, Roten A, Churilov L, Archer JS. DBS of thalamic centromedian nucleus for Lennox-Gastaut syndrome (ESTEL Trial)[J]. Ann Neurol, 2022, 91:253-267.
[53] Qiu Y, O'Neill N, Maffei B, Zourray C, Almacellas-Barbanoj A, Carpenter JC, Jones SP, Leite M, Turner TJ, Moreira FC, Snowball A, Shekh-Ahmad T, Magloire V, Barral S, Kurian MA, Walker MC, Schorge S, Kullmann DM, Lignani G. On-demand cell-autonomous gene therapy for brain circuit disorders[J]. Science, 2022, 378:523-532.
[54] Zhang L, Wang Y. Gene therapy in epilepsy[J]. Biomed Pharmacother, 2021, 143:112075.
[55] Paul B, Montoya G. CRISPR-Cas12a:functional overview and applications[J]. Biomed J, 2020, 43:8-17.

选择文件类型/文献管理软件名称

选择包含的内容

2 2022年癫痫领域十大研究进展

Research progress on epilepsy in 2022

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘明生. 周围神经和肌肉超声成像在神经肌肉病诊断中应用[J]. 中国现代神经疾病杂志, 2023, 23(9): 771-774.
[2]	万雅兰, 于佳希, 邓健文, 洪道俊, 王朝霞. 短串联重复序列相关神经肌肉病临床及机制研究进展[J]. 中国现代神经疾病杂志, 2023, 23(9): 775-781.
[3]	李淑华, 苏闻, 陈海波. 功能性肌张力障碍诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(9): 844-849.
[4]	王亚伟, 田锋. 不同性别动脉粥样硬化差异性研究进展[J]. 中国现代神经疾病杂志, 2023, 23(9): 864-871.
[5]	薛蓉, 张轩. 睡眠障碍对脑血管病的影响[J]. 中国现代神经疾病杂志, 2023, 23(8): 659-662.
[6]	张鹏, 陈涛, 许莉. 成人失眠认知行为疗法关键技术与流程改进建议[J]. 中国现代神经疾病杂志, 2023, 23(8): 663-667.
[7]	张轩, 薛蓉. 特发性快速眼动睡眠期行为障碍向神经系统变性疾病转化的生物学标志物研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 668-673.
[8]	刘引, 汤永红, 翟锦霞, 邱媛. 慢性低度炎症与睡眠障碍研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 674-677.
[9]	于洁洋, 张亚男, 李惠敏, 黄真灿, 李宛儒, 王赞. 发作性睡病与焦虑研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 678-682.
[10]	库成心, 邓丽影, 谢亮. 缺血性卒中继发日间过度思睡研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 683-686.
[11]	姜佳凤, 赵莲花, 赵伟. 褪黑素在阿尔茨海默病病理损害机制中的作用[J]. 中国现代神经疾病杂志, 2023, 23(8): 687-692.
[12]	黄沛, 王刚. 功能性帕金森综合征诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(8): 738-741.
[13]	洪涛, 唐斌. 如何成为一名优秀的颅底外科医师[J]. 中国现代神经疾病杂志, 2023, 23(7): 571-574.
[14]	张庆硕, 宋丹丹, 周世越, 张金璐, 韩晓旭, 许顺良. 功能性步态障碍诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(7): 604-609.
[15]	潘希娟, 邢英琦, 刘玉梅. 脑小血管病影像学评分方法[J]. 中国现代神经疾病杂志, 2023, 23(7): 633-637.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

2 2022年癫痫领域十大研究进展

Research progress on epilepsy in 2022

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价